GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mycenax Biotech Inc (ROCO:4726) » Definitions » Cyclically Adjusted Revenue per Share

Mycenax Biotech (ROCO:4726) Cyclically Adjusted Revenue per Share : NT$3.89 (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Mycenax Biotech Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Mycenax Biotech's adjusted revenue per share for the three months ended in Mar. 2025 was NT$0.588. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$3.89 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Mycenax Biotech's average Cyclically Adjusted Revenue Growth Rate was 8.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 13.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Mycenax Biotech was 17.80% per year. The lowest was 13.30% per year. And the median was 15.55% per year.

As of today (2025-05-29), Mycenax Biotech's current stock price is NT$38.90. Mycenax Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was NT$3.89. Mycenax Biotech's Cyclically Adjusted PS Ratio of today is 10.00.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Mycenax Biotech was 20.81. The lowest was 7.92. And the median was 12.69.


Mycenax Biotech Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Mycenax Biotech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mycenax Biotech Cyclically Adjusted Revenue per Share Chart

Mycenax Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.14 2.61 3.15 3.50 3.80

Mycenax Biotech Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.59 3.66 3.76 3.80 3.89

Competitive Comparison of Mycenax Biotech's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Mycenax Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mycenax Biotech's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mycenax Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Mycenax Biotech's Cyclically Adjusted PS Ratio falls into.


;
;

Mycenax Biotech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Mycenax Biotech's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.588/134.9266*134.9266
=0.588

Current CPI (Mar. 2025) = 134.9266.

Mycenax Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.070 100.684 0.094
201509 0.552 100.392 0.742
201512 0.517 99.792 0.699
201603 0.091 100.470 0.122
201606 0.274 101.688 0.364
201609 0.785 101.861 1.040
201612 0.655 101.863 0.868
201703 0.230 102.862 0.302
201706 0.679 103.349 0.886
201709 1.143 104.136 1.481
201712 0.846 104.011 1.097
201803 0.159 105.290 0.204
201806 0.445 106.317 0.565
201809 0.541 106.507 0.685
201812 0.786 105.998 1.001
201903 0.558 107.251 0.702
201906 0.911 108.070 1.137
201909 0.612 108.329 0.762
201912 1.027 108.420 1.278
202003 0.546 108.902 0.676
202006 2.120 108.767 2.630
202009 1.190 109.815 1.462
202012 1.387 109.897 1.703
202103 2.173 111.754 2.624
202106 0.695 114.631 0.818
202109 1.013 115.734 1.181
202112 1.440 117.630 1.652
202203 1.462 121.301 1.626
202206 0.990 125.017 1.068
202209 1.031 125.227 1.111
202212 0.984 125.222 1.060
202303 0.674 127.348 0.714
202306 1.068 128.729 1.119
202309 0.548 129.860 0.569
202312 0.889 129.419 0.927
202403 0.390 131.776 0.399
202406 0.967 132.554 0.984
202409 1.013 133.029 1.027
202412 0.940 133.157 0.952
202503 0.588 134.927 0.588

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Mycenax Biotech  (ROCO:4726) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Mycenax Biotech's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=38.90/3.89
=10.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Mycenax Biotech was 20.81. The lowest was 7.92. And the median was 12.69.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Mycenax Biotech Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Mycenax Biotech's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Mycenax Biotech Business Description

Industry
Traded in Other Exchanges
N/A
Address
No.66, Shengyi 2nd Road, 7th Floor, Hsinchu Science Park, Hsinchu County, Zhubei, TWN, 302041
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards.

Mycenax Biotech Headlines

No Headlines